The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study. (Q53183707)
Jump to navigation
Jump to search
scientific article published in June 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study. |
scientific article published in June 2007 |
Statements
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study (English)
Zev M Sthoeger
Abraham Eliraz
Ilan Asher
Neville Berkman